|

Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)

RECRUITINGSponsored by University Hospital, Basel, Switzerland
Actively Recruiting
SponsorUniversity Hospital, Basel, Switzerland
Started2024-12-10
Est. completion2029-06
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06526364

Summary

This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as well as (ii) to investigate digital biomarkers allowing the continuous clinical monitoring of those patients.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥18
* Participants are willing and able to comply with the protocol, including undergoing data and samples collection as well as study visits and examinations.
* Signed informed consent form
* In possession of a Healios+Me app compatible smartphone (iOS/Android)
* Corrected close visual acuity of ≥0.5
* Hand motor skills sufficient for using a smartphone
* Ability to follow the study procedures
* Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (clinically isolated syndrome, RRMS, SPMS, PPMS) AND early disease stages (\< 3 years) OR transitioning phase to progressive disease as evaluated based on Expanded Disability Status Scale (EDSS).
* Enrolled in the SMSC at University Hospital Basel

There are no specific exclusion criteria.

Conditions4

Multiple SclerosisMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive

Browse More Trials

Multiple Sclerosis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.